Haematological Biomarkers and Prognosis in Locally Advanced and Metastatic Oesophago-gastric Adenocarcinoma
AuthorsDevlin O1, Devlin MJ1, Feeney L1, Gallagher P1, Crawford K1, Campbell R1, Harrison C1, Purcell C1, Eatock M1, Turkington RC1,2
Departments / Institutions1 Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland. 2 Centre for Cancer Research and Cell Biology, Queen’s University of Belfast, Belfast, Northern Ireland.
Publication DateAutumn 2017
Survival outcomes in advanced oesophago-gastric adenocarcinoma are poor and there is a need to improve patient stratification to aid clinical decision-making.
We sought to evaluate neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR) and other haematological biomarkers in an advanced oesophago-gastric adenocarcinoma population.
183 patients with locally advanced or metastatic oesophago-gastric adenocarcinoma were treated with Epirubicin, Cisplatin and 5-Fluorouracil/Capecitabine (ECF/X) chemotherapy at the Northern Ireland Cancer Centre between 2007 and 2012. Haematological parameters were measured prior to administration of the first cycle of chemotherapy. Survival analysis was performed using the Kaplan-Meier method with Hazard ratios (HR) calculated using the log-rank test.
High NLR was defined as a value above the median of 4.1 and was associated with poor overall survival (HR 1.44, 95% CI 1.07-1.94, p=0.016) (Figure 1). A median OS of 8.4 and 11.5 months was observed in the high and low NLR groups respectively. High PLR also correlated with poor survival (HR 1.58, 95% CI 1.17-2.14; p=0.003).
Other haematological parameters which predicted a poor prognosis included Haemoglobin (Hb) ≤10 (HR 2.17, 95% CI 1.27-3.71; p=0.005) with a median OS of 7.0 and 10.7 months for Hb ≤10 and >10 respectively and Alkaline Phosphatase (ALP) greater than the upper normal range (HR 2.33, 95% CI 1.46-3.71; p=0.0004) (Figure 2).
NLR, PLR and other haematological biomarkers measured prior to administration of palliative chemotherapy for oesophago-gastric adenocarcinoma are predictive of prognosis.
Event takes place on October 14, 2021
Download our latest Documents